Page 37 - Nih Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Over the last two years despite budget proposals that would have cut nih on a bipartisan basis, we have added $2 billion each year to nih research. but that's across every possible disease stage for basic and advanced medical research to affect everything from alzheimer's to psoriasis, so frankly getting more money into critical, deadly cancer research is my focus. we can encourage the nih to make it a priority. there is this defense military research program i mentioned where i'm trying to direct this year $10 million. but i think we can and should do more. i hosted dr. francis collins the he...

And in my view if we really want to get medicines to people then we go about it in the way that we've always gone about it, sanjay. and that's called nih research, clinical trials, fda approval. and the reason we have that as you know, sanjay, is because of safety, efficacy and risk. >> it's a fair point. but the president's commission did not recommend any research into medical marijuana nor any of its compounds, including nonpsychoactive cbd. a mistake, a missed opportunity according to researchers like yasmin hurd. >> it should just be treated like everything else. let it have its due proce...

From a marijuana overdose. would you say that cannabis is saver than opioids? is that a fair statement to make? >> in terms of overdoses, absolutely. >> if physical pain is treated in this way, and in a way less risky, when the midst of this opioid epidemic, isn't that worth considering? >> no. it's -- it seems eminently sensible to if you're looking at the lesser of two evils but by that logic, you know, we would be accepting a lot of stuff in this country and in my view if we really want to get medicines to people then we go about it in the way that we have always gone about it, sanjay. and ...

Safer than opioids? is that a fair statement to make? >> in terms of overdoses, absolutely. >> if physical pain is treated in this way, and in a way less risky, when the midst of this opioid epidemic, isn't that worth considering? >> no. it's -- it seems eminently sensible to if you're looking at the lesser of two evils but by that logic, you know, we would be accepting a lot of stuff in this country and in my view if we really want to get medicines to people then we go about it in the way that we have always gone about it, sanjay. and that's called nih research, clinical trials, fda approval....

Ultimately, i think the more we diminish dependents on third-party payers and allow the evolution of a market that responds to individuals, individuals will demand that information. >> right. >> the convway they do in every other market. last thing i want to touch on has to do with nih research, specifically alzheimer's. it is my view that we ought to think of alzheimer's has a disease in a category of its own. and i say that because it is -- there is no disease like it that we know of that afflicts americans today. there are 5.2 million americans with the disease right now. it's 100% fatal. i...